9 Facts About Stellate Ganglion Block as a Hot Flash Treatment
When hot flashes are relentless and hormone therapy is off the table — because of breast cancer, blood clot history, or personal choice — the feeling of being out of options is its own kind of suffering. Finding out that a procedure most doctors haven't even mentioned exists, and that it actually works for a lot of women, can feel equal parts hopeful and frustrating. Nobody should have to stumble across this accidentally.
Learn more about Rose →It's a nerve block, not a hormone treatment
Stellate ganglion block (SGB) involves injecting a local anesthetic into a cluster of nerves in the neck called the stellate ganglion, which is part of the sympathetic nervous system. It has nothing to do with estrogen or any other hormone — it works by interrupting nerve signaling rather than replacing what the ovaries are no longer producing. This is exactly why it's relevant for women who cannot use hormonal treatments.
The stellate ganglion connects to the brain's temperature control center
Researchers believe hot flashes are partly driven by changes in the hypothalamus — the brain region that regulates body temperature — which becomes hypersensitive as estrogen declines. The stellate ganglion has neural pathways that feed into this system, and blocking its activity appears to reduce the hypothalamus's hair-trigger response to tiny temperature fluctuations. This is the leading physiological explanation for why the procedure helps with vasomotor symptoms specifically.
Clinical trials show it significantly reduces hot flash frequency
The most rigorous evidence comes from a randomized, sham-controlled trial published in Menopause (2022), which found that women receiving SGB had a 52% reduction in moderate-to-severe hot flash scores at four weeks compared to 30% in the sham group — a statistically significant difference. An earlier Phase II trial led by Dr. Marc Lipman showed similar patterns, with effects lasting six months or longer in many participants. These are not small effect sizes for a non-hormonal option.
It was originally developed for pain and cardiovascular conditions
SGB has been used in anesthesia and pain medicine since the 1920s for conditions including complex regional pain syndrome, post-traumatic stress disorder, and certain cardiac arrhythmias. Its application to hot flashes emerged partly from military medicine, where it was being studied for PTSD-related symptoms in veterans and clinicians noticed collateral improvements in sweating and temperature regulation. The hot flash application is relatively new but builds on decades of procedural safety data.
The injection is guided by ultrasound or fluoroscopy
SGB is not a blind injection — it's performed using real-time imaging guidance, typically ultrasound or fluoroscopic X-ray, to place a needle precisely at the C6 vertebral level in the neck where the stellate ganglion sits. The procedure takes roughly 15–30 minutes and is done under local anesthesia in an outpatient setting. The imaging guidance is what distinguishes modern SGB from older techniques and significantly improves its safety profile.
Side effects are usually temporary and mild
The most common immediate side effect is Horner's syndrome — a drooping eyelid, smaller pupil, and reduced sweating on one side of the face — which sounds alarming but is a predictable, temporary effect of blocking the sympathetic nerves in that region and typically resolves within a few hours. Hoarseness and a sensation of warmth or heaviness in the arm are also commonly reported and short-lived. Serious complications, including vascular injection or nerve injury, are rare when the procedure is performed by an experienced practitioner using imaging guidance.
It's particularly relevant for breast cancer survivors
Women who have had hormone-receptor-positive breast cancer are typically advised to avoid estrogen therapy, yet many experience severe hot flashes — sometimes worsened by aromatase inhibitors or tamoxifen used to reduce recurrence risk. SGB has been specifically studied in this population, with several trials showing meaningful symptom reduction without affecting hormone levels or cancer-related biomarkers. For this group, SGB represents one of the few evidence-backed options that doesn't carry a theoretical hormonal risk.
Effects can last months, and a second injection may extend them
In clinical studies, symptom relief from a single SGB injection has been reported to last anywhere from three months to over a year, with considerable individual variation. Some practitioners offer a second injection on the opposite side of the neck, or a repeat injection at the same site, when effects begin to wear off — and preliminary data suggest this can restore benefit. Long-term durability data are still limited, which is one reason SGB remains categorized as an emerging rather than first-line treatment.
Access and cost remain significant barriers for most women
SGB for hot flashes is not yet widely available — it requires a specialist comfortable with both the procedure and its application to vasomotor symptoms, and most gynecologists are not trained to perform it. Insurance coverage in the United States and other countries is inconsistent, with many plans classifying it as experimental for this indication, leaving out-of-pocket costs that can range from several hundred to over a thousand dollars per injection. Awareness among both patients and clinicians remains low, which means many women who might benefit are simply never told it exists.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.